Dapagliflozin
D1699C00001
Phase 3 small_molecule completed
Quick answer
Dapagliflozin for Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed